JP2007153741A - Agent for suppressing accumulation of fat surrounding kidney - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To suppress the accumulation of fat surrounding the kidney and reduce the risk of circulatory organ system diseases. <P>SOLUTION: The agent for suppressing the accumulation of fat surrounding the kidney contains a fungus body obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri, or its cultured substance as an effective component. Also, a food and drink for suppressing the accumulation of fat surrounding the kidney comprising such an effective component, is provided. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention suppresses the accumulation of perirenal fat and reduces perirenal fat among the accumulation of intraperitoneal visceral fat, which has been widely recognized as a pathology of hypertension, diabetes, hyperlipidemia and arteriosclerotic disease In particular, the present invention relates to a perirenal fat accumulation inhibitor containing, as an active ingredient, a culture of Lactobacillus gasseri and / or bacterial cells. The present invention also relates to a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or a food and drink for suppressing accumulation of perirenal fat to which bacterial cells are added.

  Accumulation of intra-abdominal visceral fat is positively correlated with blood glucose level, serum cholesterol level, and triglyceride level during glucose load not only in obese but also non-obese, and also positively correlated with systolic blood pressure and diastolic blood pressure In addition, it has been shown to be an extremely frequent basic pathology of diseases such as diabetes, hyperlipidemia, and hypertension (see, for example, Non-Patent Documents 1 and 2). Therefore, suppressing the accumulation of visceral fat is considered to enable the treatment and prevention of various pathological conditions caused by the accumulation of visceral fat (see, for example, Non-Patent Document 3).

  In particular, many active substances (hormones, otachoids, neurotransmitters, etc.) are produced and released in the kidney, and these are also collectively referred to as kidney hormones. In particular, prostaglandins are involved in blood pressure regulation and sodium metabolism, and thromboxane is involved in vasoconstriction. In addition, renin, which is a starting material of the pressor system, and erythropoietin, which is an erythropoiesis system, are also produced in the kidney. In this way, it is said that when visceral fat accumulates around the kidney, which also has an important function in the endocrine system, various metabolic abnormalities occur, and in particular, a bioregulatory function involved in circulatory system diseases called lifestyle-related diseases Is inhibited.

In addition, vigorous discussions have been made on the relationship between visceral fat accumulation and insulin resistance, and the syndrome caused by visceral fat accumulation is based on insulin resistance in the middle with visceral fat accumulation upstream, or It is recognized that this is brought about independently.
In particular, it has been shown that when there is a lot of fat around the kidney, the risk of circulatory disease increases through insulin resistance (see Non-Patent Document 4, for example). Although the visceral fat amount around the kidney is smaller than the visceral fat amount in other intestinal tracts, it shows that the accumulation of visceral fat around the kidney has a great influence on the cardiovascular disease.
Therefore, it is extremely important not to increase visceral fat around the kidney from the viewpoint of prevention of circulatory diseases even when compared with other intestinal fats.

Currently, exercise therapy, diet therapy, behavior therapy and drug therapy are used as means for reducing visceral fat. Among these drugs, drugs that centrally suppress appetite have been developed for pharmacotherapy, and β ₃ adrenergic receptor stimulants and drugs that inhibit fat absorption from the gastrointestinal tract have been tried. However, these so-called anti-obesity drugs have not been confirmed to be effective in reducing visceral fat, particularly visceral fat around the kidney, and an effective drug therapy for reducing visceral fat around the kidney has not been established. Moreover, a diet that can be taken as a daily diet or as a supplement has not been established.
On the other hand, Lactobacillus gasseri is a lactic acid bacterium used in fermented milk and the like. An example is disclosed in which a mixed culture of Lactobacillus gasseri and Bifidobacterium longum is administered to a diabetes model mouse to test whether it contributes to diabetic symptom improvement (see, for example, Patent Document 1). However, it does not confirm the effectiveness against visceral fat reduction around the kidney. Further, a visceral fat accumulation-preventing composition or obesity-treating composition containing a mold culture such as Aspergillus oryzae, a lactic acid bacteria culture such as Streptococcus faecalis and yeast is disclosed (for example, see Patent Document 2). However, since the three types are cultured and mixed, the production becomes complicated. However, the present invention has an advantage that it is a gasseri simple substance and is easy to produce.
Japanese Unexamined Patent Publication No. 2000-252770 Japanese Patent Laid-Open No. 2004-99539 Fujioka, S., et al .: Metabolism 36: 54-59, 1987 Matsuzawa, Y., et al .: Progress in Obesity Research, p309-312, 1990 Bray, GA, Obesity Research, Suppl.4,425S-434S, 1995 D. Rudman & PW Shank, Endocrinology, vol. 79, 565-571, 1966.

The present inventors have been researching lactic acid bacteria having colonization in the human intestinal tract, and obtained by culturing lactic acid bacteria having colonization in the intestinal tract, particularly lactic acid bacteria belonging to Lactobacillus gasseri. When a product and / or microbial cells are administered, these microorganisms settle in the intestinal tract and act on the host to find that they have an effect of suppressing fat accumulation around the kidney, and the present invention has been completed.
That is, an object of the present invention is to provide a culture product obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri and / or a fat accumulation inhibitor around the kidney containing the microbial cell as an active ingredient. .
Another object of the present invention is to provide a culture product obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or a food and drink for suppressing accumulation of fat around the kidney containing the cells.

  The present inventors have been studying lactic acid bacteria having fixability in the human intestinal tract. Among lactic acid bacteria isolated from fermented milk and lactic acid bacteria derived from humans, Lactobacillus gasseri (Lactobacillus gasseri), in particular, We found that it has high intestinal colonization, but found that this Lactobacillus gasseri (Lactobacillus gasseri) suppresses fat accumulation around the kidney which was not known so far. As a result, the present invention was completed.

  That is, the present invention relates to a culture product obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri and / or a fat accumulation inhibitor around the kidney containing the microbial cell as an active ingredient. Furthermore, this invention relates to the food-drinks for fat accumulation suppression around the kidney which contain such an active ingredient.

Accordingly, the present invention is an invention having the following configuration.
(1) A perirenal fat accumulation inhibitor comprising as an active ingredient a culture and / or fungus body of Lactobacillus gasseri.
(2) The perirenal fat accumulation inhibitor according to (1), wherein the Lactobacillus gasseri is Lactobacillus gasseri SBT2055 or Lactobacillus gasseri JCM1131.
(3) A food and drink for suppressing accumulation of perirenal fat to which a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or fungus bodies is added.

According to the present invention, a culture of Lactobacillus gasseri (Lactobacillus gasseri) and / or a perirenal fat accumulation inhibitor containing as an active ingredient, and further culturing a lactic acid bacterium belonging to Lactobacillus gasseri It is possible to provide a food and drink for inhibiting the accumulation of perirenal fat, which comprises the obtained culture and / or microbial cells as active ingredients.
Since the perinephric fat accumulation inhibitor and food and drink for inhibiting perirenal fat accumulation provided by the present invention use Lactobacillus gasseri, which is a lactic acid bacterium that has been used for fermented milk, cheese, and the like since ancient times. It has no toxicity and side effects, and can be taken daily as a supplement for suppressing accumulation of perirenal fat, and as a food or drink for suppressing accumulation of perirenal fat, and is extremely useful.

Among the many lactic acid bacteria derived from fermented milk and humans, the present inventors have high gastric acid tolerance, good growth under low pH conditions, high human intestinal cell affinity and high human intestinal tract affinity. The selection of strains that are resistant to bile acids, colonize in the intestinal tract, have high survival when applied to foods, and have excellent flavor and physical properties has been promoted. Next, among the lactic acid bacteria showing high colonization in the human intestinal tract, the selection was made under the condition of suppressing the accumulation of perirenal fat, and the lactic acid bacteria belonging to Lactobacillus gasseri were found in the intestinal tract. It was found that it has the effect of suppressing the accumulation of perirenal fat by fixing.
Among the lactic acid bacteria belonging to Lactobacillus gasseri, Lactobacillus gasseri SBT2055 strain and Lactobacillus gasseri JCM1131 strain could be selected as strains meeting the above conditions. The SBT2055 strain is deposited at the Patent Microorganism Deposit Center of the National Institute of Advanced Industrial Science and Technology under the deposit number FERM P-15535. The JCM1131 strain is a publicly available strain of RIKEN.

  In particular, Lactobacillus gasseri strain SBT2055 has a high affinity for human intestinal cells, and when orally administered, it can survive and reach the intestinal tract and is resident in the intestinal tract for a long time. It is possible to act on the host by growing in the intestine and to suppress the accumulation of perirenal fat. Lactobacillus gasseri (Lactobacillus gasseri) administered from outside the body has been established in the intestine and exhibits no such physiological effect, and has been revealed for the first time by the present inventors.

  Furthermore, in the present invention, not only the above-mentioned bacteria, but also Lactobacillus gasseri isolated from humans and fermented milk, and any of those that are established in the intestine and exhibit the above-described action But you can use it. A mutant strain of Lactobacillus gasseri that exhibits the above action can also be used.

  Next, the culture method of these lactic acid bacteria is described. As the medium for Lactobacillus gasseri of the present invention, various media such as a milk medium or a medium containing milk components and a semi-synthetic medium not containing this can be used. An example of such a medium is a reduced skim milk medium obtained by reducing skim milk and then heat sterilizing. The culture method is a static culture or a neutralization culture in which pH is controlled to be constant. However, the culture method is not particularly limited as long as the bacteria grow well. Bacteria are cultured according to a conventional method of lactic acid bacteria culture, and those isolated from the obtained culture by means of collecting bacteria such as centrifugation can be used as they are as the active ingredient of the present invention. In addition to cells isolated purely as cells, cultures, suspensions, other cell-containing materials, and cytoplasm and cell wall fractions obtained by treating cells with enzymes and physical means Can be used.

  Furthermore, in formulation, excipients, stabilizers, flavoring agents, and the like that are permitted in the formulation are mixed as appropriate and concentrated, freeze-dried, or dried by heating to form dead cells. These dried products, concentrates, and pastes are also included. In addition, it is formulated by mixing excipients, binders, disintegrants, lubricants, flavoring agents, suspending agents, coating agents, and other optional agents as long as they do not interfere with the action of the cells and culture. It can also be converted. The dosage form can be tablets, pills, capsules, granules, powders, powders, syrups, etc., and these are preferably administered orally.

The dosage is appropriately determined individually in consideration of the symptom, age, etc. of the subject of administration, but is usually 0.5 to 10 g as a dry product per day for an adult, and this may be divided into several times a day. . The content ratio of lactic acid bacteria is not particularly limited, and may be appropriately adjusted in accordance with ease of production, a preferable daily dose, and the like. For example, when the dosage form is liquid, it is preferably 1 × 10 ⁵ cells / ml to 1 × 10 ¹⁰ cells / ml, and when it is solid, 1 × 10 ⁵ cells / g to 1 × 10 ¹⁰ cells. / g is preferable. By taking in this way, it settles in the intestinal tract and exhibits the desired effect.

  Moreover, you may add the active ingredient of this invention to a raw material during the manufacturing process of food-drinks. As the food and drink, any food and drink may be used. Examples thereof include milk drinks, fermented milk, fruit juice drinks, jelly, candy, dairy products, processed egg products such as mayonnaise, foods such as butter cake and other confectionery and breads. Can give. When used as a living microbial cell, Lactobacillus gasseri (Lactobacillus gasseri) strain or its mutant cell itself, and fermented milk obtained by culturing the lactic acid bacterium cell, cheese itself, These cells, fermented milk, cheese and the like may be used as a raw material to make bread, snacks, cakes, puddings and the like.

Since these perrenal fat accumulation inhibitors or foods and drinks for perirenal fat accumulation inhibition have the ability to inhibit perirenal fat accumulation, the prevention and treatment of the various pathologies caused by perirenal fat accumulation described above. Can be very beneficial to improvement.
Lactic acid bacteria have been used for the production of fermented milk and cheese since ancient times, and the present invention has a feature that there is no problem in safety of the perirenal fat accumulation-inhibiting agent or perirenal fat accumulation-inhibiting food and drink.

  Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, these are merely illustrative and the present invention is not limited thereto.

(Preparation of Lactobacillus gasseri culture powder, 1)
Reduced skim milk medium (13 wt% skim milk powder, containing 0.5 wt% yeast extract) is sterilized at 95 ° C for 30 minutes, then inoculated with Lactobacillus gasseri SBT2055 strain and cultured at 37 ° C for 16 hours. The culture was freeze-dried to obtain a Lactobacillus gasseri strain SBT2055 culture powder. This can be used as it is as a perirenal fat accumulation inhibitor of the present invention.

(Preparation of Lactobacillus gasseri culture powder, 2)
Reduced skim milk medium (13% by weight skim milk powder, containing 0.5% by weight yeast extract) is sterilized at 95 ° C for 30 minutes, then inoculated with Lactobacillus gasseri strain JCM1131 and cultured at 37 ° C for 16 hours. The culture was freeze-dried to obtain a Lactobacillus gasseri strain JCM1131 culture powder. This can be used as it is as a perirenal fat accumulation inhibitor of the present invention.

[Test Example 1]
(Lactobacillus gasseri culture administration and fat weight measurement)
The Lactobacillus gasseri strain SBT2055 (LG SBT2055) culture powder obtained in Example 1 and the Lactobacillus gasseri strain JCM1131 strain (LG JCM1131) culture powder obtained in Example 2 are shown in Table AIN-76G. Were formulated as LG SBT2055 diet and LG JCM1131 diet, respectively, and administered to rats, and fat accumulation in 3 sites of perirenal, epididymal and retroperitoneal cavity was examined. On the other hand, a reduced skim milk medium sterilized at 95 ° C. for 30 minutes was freeze-dried to prepare a control powder, which was blended in the control food shown in Table 1 in accordance with AIN-76G.
Thirty four-week-old Fischer male rats were allowed to take control foods freely and bred for 1 week, then divided into three groups of 10 animals, one group continued to receive control food, and another group received LG SBT2055 food. In another group, the LG JCM1131 diet was freely consumed and reared for an additional 4 weeks, and then laparotomy was performed. And separated, and the weight was measured. In addition, the total weight of adipose tissue at three sites was measured.
There were no differences in body weight, food intake, or fecal weight among the three groups.

[Table 1]
(g / kg)
───────────────────────────────────
Control meal LG SBT2055 meal LG JCM1131 meal ───────────────────────────────────
Casein 125 125 125
Control powder 200--
LG SBT2055 culture powder-200-
LG JCM1131 culture powder--200
DL-methionine 3.0 3.0 3.0
Lard 90 90 90
Corn oil 10 10 10
Mineral mixing 35 35 35
Vitamin mix 10 10 10
Choline bitartrate 2.0 2.0 2.0
Cellulose 50 50 50
α-Corn starch 150 150 150
Sodium cholate 1.5 1.5 1.5
Cholesterol 5 5 5
Sucrose 318.5 318.5 318.5
───────────────────────────────────
Total 1000 1000 1000
───────────────────────────────────

The results obtained by measuring the adipose tissue weight and the total adipose tissue weight at the three sites of the perirenal, epididymis and retroperitoneal space are shown in FIGS. According to this, the weight of epididymal adipose tissue was not significantly different between the control diet group, the LG SBT2055 diet group, and the LG JCM1131 diet group, but the fat in the perirenal and retroperitoneal space The total weight of the tissue and adipose tissue was significantly decreased in the LG SBT2055 food intake group and the LG JCM1131 food intake group compared to the control food intake group. That is, it was confirmed that the food added with the Lactobacillus gasseri SBT2055 culture powder and the Lactobacillus gasseri JCM1131 culture powder significantly reduced the weight of adipose tissue around the kidney.
From the above results, it is clear that food supplemented with Lactobacillus gasseri culture powder has the effect of significantly reducing the weight of adipose tissue around the kidney, which has been shown to increase the risk of cardiovascular disease It became.

(Manufacture of tablets)
A liquid culture of Lactobacillus gasseri strain SBT2055 was centrifuged at 4 ° C. and 7,000 rpm for 15 minutes and washed with sterilized water, and this was repeated three times to obtain washed cells. This was freeze-dried to obtain cell powder. 4 parts of skim milk powder are mixed with 1 part of this bacterial powder, and 1 g of this mixed powder is tableted by a conventional method with a tableting machine to prepare a tablet containing 200 mg of Lactobacillus gasseri strain SBT2055 strain of the present invention. did.

(Manufacturing fermented milk)
Lactobacillus gasseri strain SBT2055 was cultured in MRS liquid medium (Difco). Each culture solution in the logarithmic growth phase was inoculated with 1% of 10% reduced skim milk (115 ° C., sterilized for 20 minutes) supplemented with 0.3% yeast extract to prepare a mother culture. 10% reduced skim milk was added thereto, and 2.5% was added to the yogurt mix heated at 100 ° C. for 10 minutes. Fermentation was performed at 37 ° C., and cooling was performed when the lactic acid acidity reached 0.85, and the fermentation was terminated. Thus, fermented milk for inhibiting perirenal fat accumulation according to the present invention was obtained.

(Manufacture of powder)
Lactobacillus gasseri SBT2055 strain cells were inoculated into 5 L of MRS liquid medium (Difco), followed by stationary culture at 37 ° C. for 18 hours. After completion of the culture, centrifugation was performed at 7,000 rpm for 15 minutes to obtain 1/50 amount of concentrated bacterial cells of the culture solution. Next, the concentrated cells were mixed with the same amount of a dispersion medium containing 10% by weight of skim milk powder and 1% by weight of sodium glutamate, adjusted to pH 7, and then freeze-dried. The obtained lyophilized product was sized with a 60 mesh sieve to produce a lyophilized bacterial powder. In accordance with the provisions of the 13th revised Japanese Pharmacopoeia Guideline General Formulation “Powder”, 1 g of this lyophilized powder is added with 400 g of lactose (JP) and 600 g of potato starch (JP), and mixed uniformly. A powder for suppressing perirenal fat accumulation was obtained.

(Preparation of stick health food)
Lactobacillus gasseri SBT2055 strain culture powder obtained in Example 1 was mixed with 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, and 60 g of an equal mixture of corn starch and lactose. The mixture was packed in a stick-shaped bag to produce a stick-shaped health food for suppressing perirenal fat accumulation according to the present invention.

It is the figure which showed the result of having compared the total weight of the fat tissue. (Examples 1 and 2) It is the figure which showed the result of having compared the fat tissue weight of the epididymis. (Examples 1 and 2) It is the figure which showed the result of having compared the fat tissue weight around a kidney. (Examples 1 and 2) It is the figure which showed the result of having compared the fat tissue weight of the retroperitoneal space. (Examples 1 and 2)

Claims (3)

  A perirenal fat accumulation inhibitor comprising as an active ingredient a culture and / or fungus body of Lactobacillus gasseri exhibiting high colonization in the human intestine.   The perirenal fat accumulation inhibitor according to claim 1, wherein the Lactobacillus gasseri exhibiting high fixability in the human intestinal tract is Lactobacillus gasseri SBT2055 or Lactobacillus gasseri JCM1131. A culture product obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri showing high fixability in the human intestinal tract and / or a food and drink for suppressing accumulation of perirenal fat to which microbial cells are added.